Polymorphically acetylated aminoglutethimide in humans.

The urinary excretion during 24 h of aminoglutethimide (AG) its major metabolite (N-acetylAG) and two minor metabolites (N-formylAG and nitroG) were measured in 10 volunteers given AG who had been typed for acetylator phenotype using sulphadimidine. The slow acetylators of sulphadimidine excreted more AG (mean 28% of the administered dose) than did the fast acetylators (12%), but the latter excreted more of the dose as N-acetylAG (8.8%) than did the former (3.9%). NitroG and N-formylAG were minor urinary metabolites of AG in humans. The former was more abundant in the urine of slow acetylators (0.10% of the dose) than in that of fast acetylators (0.047%), whereas the respective proportions of doses excreted as the N-formyl derivative (0.475 and 0.465%) were not significantly different for the two acetylator phenotypes. These results show that AG is among those drugs that are polymorphically acetylated in humans.     

Intracranial tumors simulating the presentation of cerebrovascular syndromes: Early detection with cerebral computed tomography (CCT)

One hundred thirty consecutive patients in whom the initial diagnosis of cerebrovascular disease was made on clinical basis were evaluated by cerebral computed tomographic (CCT) scan. Three of 20 patients with transient ischemic attacks were found to have an abnormality on CCT scan. Of 30 patients with an initial diagnosis of stroke-in-evolution, 13 were found to have a clinically unsuspected lesion by CCT scan. Of 60 patients with completed stroke, CCT scan made possible differentiation of intracerebral hematoma, hemorrhagic and nonhemorrhagic infarction, and excluded intracranial tumors. Of 20 patients believed to have symptoms of cerebral arteriosclerosis, six had nonvascular lesions and eight had a cerebral atrophic process. This study demonstrates the efficacy of this safe and noninvasive procedure in evaluating patients with cerebrovascular disease.